1,380
Participants
Start Date
August 25, 2021
Primary Completion Date
August 16, 2023
Study Completion Date
October 4, 2023
BNT162b2
Intramuscular (IM)
Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
Intramuscular (IM)
Monovalent BNT162b2 (B.1.1.7)
Intramuscular (IM)
Monovalent BNT162b2 (B.1.617.2)
Intramuscular (IM)
Monovalent BNT162b2 (B.1.1.529.1)
Intramuscular (IM)
Observational
No vaccination within 3 months after Visit 1.
CRS Clinical Research Services Berlin, Berlin
Rochester Clinical Research, Rochester
Studienzentrum Brinkum Dr. Lars Pohlmeier und Torsten Drescher, Stuhr
Atlanta Center for Medical Research, Atlanta
Meridian Clinical Research, Savannah
Bagcilar Medipol Mega University Hospital, Istanbul
Istanbul University Medical Faculty, Istanbul
Medpharmics, LLC, Gulfport
Kocaeli Universitesi Tip Fakultesi, Kocaeli
Aventiv Research Inc., Columbus
IKF Institut fuer klinische Forschung Frankfurt, Frankfurt am Main
CRS Clinical Research Services Mannheim GmbH, Mannheim
Langeberg Medicross Medical Centre, Kraaifontein
North Texas Infectious Diseases Consultants, Dallas
Clinical Trials of Texas Inc., San Antonio
Diagnostics Research Group, San Antonio
ARC Clinical Research, Austin
Collaborative Neuroscience Network LLC, Long Beach
California Research Foundation, San Diego
Clinical Research Consulting, Llc, Milford
Stamford Therapeutics Consortium, Stamford
Amici Clinical Research, Warren Township
JOSHA Research, Bloemfontein
Paarl Research Centre, Paarl
Synexus Helderberg Clinical Trial Centre, Somerset West
Worthwhile Clinical Trials, Benoni
Tiervlei Trial Centre, Cape Town
Midrand Medical Centre, Halfway House
Newtown Clinical Research, Johannesburg
Global Clinical Trials, Pretoria
Botho ke Bontle Health Service, Pretoria
Synexus SA Stanza Clinical Research Centre, Pretoria
Jongaie Research, Medicross Pretoria West, Pretoria
Ankara University Faculty of Medicine, Avicenna Hospital, Ankara
Hacettepe University Hospital, Ankara
Lead Sponsor
BioNTech SE
INDUSTRY